Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + rituximab for splenic marginal zone lymphoma (IELSG-36)
2011-000880-28Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and bendamustine in splenic marginal zone lymphoma (SMZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Complete response rate. Started Oct 2012; status: completed.
02
Drugs
rituximabbendamustine
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2011-000880-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000880-28.